Back to discover
Drug

Plerixafor

Approved · EMA
ClassC-X-C chemokine receptor type 4 partial agonistEmerging researchLate-stage development

Also known as Mozobil, 1,1'-(1,4-phenylenebis(methylene))bis-1,4,8,11-tetraazacyclotetradecane, 1,4,8,11-tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-.

RxNorm733003ChEMBLCHEMBL18442ATCL03AX16UNIIS915P5499N
2
Research papers
20
Active clinical trials
C-X-C chemokine receptor type 4
Primary target
2
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell Disease

Clinical trial2026-08-03Primary completion · ClinicalTrials.gov

A Phase I/II Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Transplantation Followed by GVHD Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies in People Living With HIV (PLWH)

Clinical trial2026-07-30Primary completion · ClinicalTrials.gov

Phase 1/2 Trial of Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-linked Chronic Granulomatous Disease

Clinical trial2026-07-10Results expected Q4 2032 · ClinicalTrials.gov

Quadruplet Induction Followed by Teclistamab Consolidation and Doublet Maintenance in Patients With Primary Plasma Cell Leukemia: The QUANTUM Trial

Clinical trial2026-07-06Results expected Q4 2032 · ClinicalTrials.gov

A Phase I Study of MozobilTM in the Treatment of Patients With WHIMS

Clinical trial2026-07-02Results expected Q4 2026 · ClinicalTrials.gov

A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome.

Clinical trial2026-06-26Results posted · ClinicalTrials.gov

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Clinical trial2026-06-12Results expected Q4 2026 · ClinicalTrials.gov

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

Clinical trial2026-06-11Results expected Q2 2027 · ClinicalTrials.gov

A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.

Research2023-10-02The Journal of clinical investigation

Approval: Plerixafor Accord (EMA)

Regulatory2022-12-16EMA

Approval: Mozobil (EMA)

Regulatory2009-07-30EMA

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist.

Research2005-04-01The Journal of experimental medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Plerixafor
Aliases & brands
Mozobil1,1'-(1,4-phenylenebis(methylene))bis-1,4,8,11-tetraazacyclotetradecane1,4,8,11-tetraazacyclotetradecane, 1,1'-(1,4-phenylenebis(methylene))bis-
RxNorm CUI
733003
ChEMBL ID
CHEMBL18442
ATC codes
L03AX16
UNII
S915P5499N
Primary mechanism
C-X-C chemokine receptor type 4 partial agonist
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

C-X-C chemokine receptor type 4
CXCR4 · P61073
PARTIAL AGONISTC-X-C chemokine receptor type 4 partial agonist

Regulatory timeline

2 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2009-07-30
Latest approval
2022-12-16
Authorities
EMA
Total events
2
emaEuropean Medicines Agency· 2 events
2022-12-16Approval
Approval: Plerixafor Accord (EMA)
Indication: Adult patients Plerixafor Accord is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the… Show full indication

Adult patients Plerixafor Accord is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2). Paediatric patients (1 to less than 18 years) Plerixafor Accord is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.2).

Evidence ↗
2009-07-30Approval
Approval: Mozobil (EMA)
Indication: Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and… Show full indication

Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

104 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
104
registered trials across all phases
LATEST COMPLETION 2025
20
Active studies
15
Recruiting
11
Late-stage (III+)
57
Completed
27
Discontinued
PHASE DISTRIBUTIONn = 104
Early Phase 11Phase 130Phase 1 / 223Phase 239Phase 2 / 31Phase 33Phase 43Phase N / A4

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

GCSF Plus Plerixafor as First-line Treatment for Autologous Stem Cells Harvest in Children With Malignant Diseases in Need for High-dose Chemotherapy With Stem Cell Rescue.

Unknown statusPH IVTel-Aviv Sourasky Medical Centern=302020

Mobilization Test of BM Progenitor Cells With Plerixafor / AMD3100: Controlled Parallel Group Comparison Between Diabetic and Non Diabetic Subjects

CompletedPH IVUniversity of Padovan=202014

A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg

CompletedPH IVGenzyme, a Sanofi Companyn=612013

A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome.

CompletedPH II/IIINational Institute of Allergy and Infectious Diseases (NIAID)n=202021

A Prospective Randomized Trial Comparing Three Different Peripheral Stem Cell Mobilization Regimens in Patients With Symptomatic Multiple Myeloma or Lymphoma

CompletedPH IIIWeill Medical College of Cornell Universityn=472019

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Phase 1/2, Open-Label, Multicenter, Single-Arm Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease

CompletedPH I/IISangamo Therapeuticsn=72025

Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease

CompletedPH IMemorial Sloan Kettering Cancer Centern=252025

A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation With Post Transplant Maintenance for the Treatment of Systemic Sclerosis

CompletedPH IIFred Hutchinson Cancer Centern=212024

Pilot Study T Cell Depletion in the Setting of Autologous Stem Cell Transplantation for Patients With Multiple Myeloma

CompletedPH IUniversity of Chicagon=302024

Autologous Hematopoietic Stem Cell Mobilization (Plerixafor) and Immunologic Reset in New Onset Type 1 Diabetes Mellitus

CompletedPH I/IIUniversity of Albertan=222024

A Follow-Up Study to Add Whole Brain Radiotherapy (WBRT) to Standard Temozolomide Chemo-Radiotherapy in Newly Diagnosed Glioblastoma (GBM) Treated With 4 Weeks of Continuous Infusion Plerixafor

CompletedPH IILawrence D Rechtn=212024

Research activity

2 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20052023
Major research themes4
Heterocyclic Compounds1Immunologic Deficiency Syndromes1Primary Immunodeficiency Diseases1Warts1
Journals, researchers & institutions
Top journals
  • The Journal of clinical investigation1
  • The Journal of experimental medicine1
Leading researchers
  • Brewer C1
  • Bridger G1
  • Broxmeyer HE1
  • Buck CB1
  • Calandra G1
  • Calvo KR1
  • Campbell TB1
  • Cho E1
Leading institutions
free-text, unnormalised
  • Department of Laboratory Medicine1
  • Indiana University School of Medicine1
  • Laboratory of Cancer Biology and Genetics and.1
  • Laboratory of Cellular Oncology1
  • Laboratory of Clinical Immunology and Microbiology and.1
  • Laboratory of Molecular Immunology1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.